Natural Alternatives International's healthy ageing-focused beta-alanine ingredient, TriBsyn, has been proven to be bioavailable at a low dose in a novel study.
The ingredient — which has been clinically proven to aid cognition and muscular maintenance in ageing — can also prevent paresthesia, a common side effect associated with prolonged beta-alanine supplementation.
These results suggest that TriBsyn could optimise the beta-alanine supplementation experience, which is often uncomfortable for users experiencing paresthesia symptoms — which include tingling, numbness, chilling or burning throughout the body.
Beta-alanine's potential as a healthy ageing ingredient
Beta-alanine is a common, non-essential amino acid that occurs naturally in the body, and is often incorporated into dietary supplements due to its ability to support the muscles during exercise.
By facilitating the production of key muscle and brain dipeptide carnosine, beta-alanine can help to buffer lactic acid in the muscles and protect the neurones from inflammation and oxidative stress, meaning that athletes can train harder for longer.
Although this ingredient had its routes in exercise supplements, players in the nutraceutical industry have begun to acknowledge the ingredient's potential in healthy ageing, as many older individuals experience muscular and cognitive decline during the ageing process.
However, beta-alanine supplementation often comes with uncomfortable side effects such as paresthesia, which can discourage people from taking it, even though the symptom is harmless.
Therefore, Natural Alternatives International wanted to create a beta-alanine solution that was highly bioavailable to the body, but also more pleasant for the user to take regularly.
The study
To assess how TriBsyn functions as a nutraceutical, researchers at the Gdansk University of Technology conducted a randomised, double-blind, three way crossover bioavailability study in 12 healthy adults undergoing fasting.
Participants were either given a low (400mg) or high (1200mg) dose of Hydro Oleo encapsulated beta-alanine or a placebo.
Through oral intake, 400mg of TriBsyn enhanced blood beta-alanine levels 4.5x more than the same dose of conventional beta-alanine, while also almost completely eliminating paresthesia in the study participants VAS score of 0.62).
Notably, a low dose of TriBsyn still increased plasma beta-alanine levels 1.3x more than 1200mg of raw beta-alanine, highlighting the ingredient's superior bioavailability and efficacy at low doses.
Through pharmakokinetic studies, researchers also concluded that TriBsyn was absorbed through direct cellular uptake and gastrointestinal absorption — meaning effective delivery across the body at a cellular and systemic level.
“The results of this clinical trial show that TriBsyn can eliminate parasthesia and demonstrate notable pharmacokinetic efficiency simultaneously, confirming enhanced delivery and exceptional bioavailability," notes President and COO of Natural Alternatives International, Ken Wolf.
“With its advanced Hydro Oleo technology and carnosine-boosting effects, TriBsyn provides scientifically proven claims to improve muscle vitality, muscle working capacity and cognitive performance."
"It truly sets a new standard in beta-alanine supplementation and helps fill the gap for healthy ageing and wellness solutions—especially for the active ageing population, GLP-1 users, and those with plant-based diets.”
Read more
Study reveals cognitive benefits of NAI's beta-alanine tablets
Nutrabolt extends patent license for CarnoSyn beta-alanine
ADM reveals the top active nutrition trends in the run-up to the olympic games